DAPA-HF also showed benefit regardless of baseline QoL
PHILADELPHIA – Heart failure with reduced ejection fraction appears to respond to dapagliflozin (Farxiga) similarly across age groups and regardless of baseline quality of life, researchers reported here in two analyses of the DAPA-HF trial.